Tarlatamab Plus Durvalumab in SCLC: DeLLphi-305 for USMLE

In a phase 3 trial called DeLLphi-305, adding tarlatamab to durvalumab as first-line maintenance therapy improved survival in extensive-stage small cell lung cancer (ES-SCLC). Median overall survival was extended by more than eight months, and the risk of death was 58% lower than with durvalumab alone. The results were presented at ESMO 2026 in Madrid and published in the New England Journal of Medicine. The trial was open-label, and the published data are an interim analysis.

What happened

DeLLphi-305 was a randomized, open-label, multicenter phase 3 study. It enrolled 563 patients with ES-SCLC who had already received standard first-line treatment (durvalumab plus platinum and etoposide chemotherapy) and had not progressed. Patients were randomized 1:1 to maintenance therapy with either tarlatamab plus durvalumab or durvalumab alone.

Reported results, as described in the source:

• Overall survival: the combination extended median overall survival by more than eight months. The median in the combination arm was 21.1 months. Risk of death was reduced by 58%.
• One-year survival: nearly 80% of patients on the combination were alive, versus 53% on durvalumab alone.
• Progression-free survival: median PFS was 7.4 vs 1.9 months. At a median follow-up of 13.9 months, the risk of progression or death was 66% lower.
• Response: six times as many patients showed anticancer activity with the combination.
• Subgroups: the survival benefit was consistent across subgroups, including patients with brain and liver metastases.
• Safety: side effects were consistent with the individual agents. They included low neutrophil counts, decreased appetite, fatigue and weight loss. Cytokine release syndrome (CRS) occurred in 49.6% of patients, was most commonly grade 1 or 2, and mostly resolved with supportive care.

According to the investigators, DeLLphi-305 is the first phase 3 study of a bispecific T-cell engager to show an overall survival benefit in first-line maintenance for ES-SCLC. Tarlatamab is already FDA-approved as a later-line therapy.

Why it matters

SCLC is among the most aggressive lung cancers and spreads early. About 80% of patients are diagnosed with extensive-stage disease. Standard first-line treatment combines chemotherapy with an immune checkpoint inhibitor, and median survival with first-line therapy has been 12 to 13 months. Frontline gains have been limited, so a median overall survival of 21.1 months stands out.

The investigators also point out that many patients relapse quickly and never reach second-line treatment. That makes improvements in the first-line setting especially important. The presenting investigator described the combination as a new standard of care in the maintenance setting. That is his assessment, and guideline bodies and regulators will make their own judgments.

What to know for the USMLE

This news touches several topics that appear on Step 1 and Step 2 CK: oncology, pathology, immunology and pharmacology.

• SCLC is a neuroendocrine tumor. It arises from neuroendocrine (Kulchitsky) cells. It is strongly associated with smoking and typically presents as a central/hilar mass.
• Histology: small blue cells with scant cytoplasm, finely granular ("salt-and-pepper") chromatin, nuclear molding, and crush artifact. Markers include chromogranin A, synaptophysin, CD56 (NCAM) and neuron-specific enolase.
• Genetics: classic loss of TP53 and RB1. MYC amplification is also described.
• Paraneoplastic syndromes: SIADH (hyponatremia), ectopic ACTH (Cushing syndrome), Lambert-Eaton myasthenic syndrome (antibodies against presynaptic voltage-gated calcium channels), and anti-Hu paraneoplastic encephalomyelitis/sensory neuropathy. Local complications include SVC syndrome.
• Staging: limited vs extensive stage. Extensive disease (metastatic, or too widespread for a single radiation field) is the most common presentation and is treated with systemic therapy rather than curative surgery.
• Standard regimen: platinum (cisplatin or carboplatin) plus etoposide, a topoisomerase II inhibitor. Remember cisplatin toxicities (nephrotoxicity, ototoxicity, neuropathy) and carboplatin myelosuppression.
• Durvalumab is an anti-PD-L1 antibody. Blocking PD-1/PD-L1 releases the brake on T cells. Know the immune-related adverse events: pneumonitis, colitis, hepatitis, thyroiditis, hypophysitis and adrenal insufficiency.
• Tarlatamab is a bispecific T-cell engager. One arm binds CD3 on T cells and the other binds DLL3 (delta-like ligand 3, a Notch pathway ligand) on SCLC cells. It physically links the two cells and activates the T cell. Textbook teaching holds that CD3 engagement activates T cells independent of MHC-restricted antigen presentation. Blinatumomab (CD19 × CD3) is another example of this drug class.
• Cytokine release syndrome: T-cell activation releases cytokines such as IL-6, causing fever, hypotension and hypoxia. Textbook management includes supportive care and, for more severe cases, the IL-6 receptor antagonist tocilizumab. Neurotoxicity (ICANS) is a recognized class effect of T-cell engagers, though the source does not report it for this trial.

Limitations

• Open-label design. Patients and clinicians knew which treatment was given. This can matter for subjective outcomes and for decisions about when to stop treatment, though overall survival is less vulnerable to this bias.
• Interim analysis. The data are early. Median follow-up for progression-free survival was 13.9 months, and results may change as follow-up lengthens.
• Selected population. Only patients who had not progressed after first-line durvalumab plus chemotherapy were randomized. The results do not apply to patients who progressed during induction.
• Toxicity. Half of the combination recipients developed CRS. Most cases were mild to moderate, but this is a real cost that needs monitoring and experienced management.
• Source limits. This article draws on a press report of the conference presentation and the NEJM publication. The source material does not give full details such as the exact control-arm median survival or detailed adverse-event tables, so refer to the paper itself for those.
• Quality of life. The source does not report quality-of-life outcomes.

FAQ

What is tarlatamab and how does it work?

Tarlatamab is a bispecific T-cell engager. It binds CD3 on T cells and DLL3 on small cell lung cancer cells. This brings the two cell types close together and enhances the immune attack on the tumor.

What did the DeLLphi-305 trial show?

In 563 patients with extensive-stage SCLC, maintenance tarlatamab plus durvalumab extended median overall survival by more than eight months versus durvalumab alone and reduced the risk of death by 58%. Median progression-free survival was 7.4 vs 1.9 months.

Is SCLC a neuroendocrine tumor on the USMLE?

Yes. SCLC is a high-grade neuroendocrine carcinoma that stains for chromogranin, synaptophysin and CD56. This explains its association with paraneoplastic syndromes such as SIADH and ectopic ACTH.

Key takeaways

• In DeLLphi-305, a randomized open-label phase 3 trial of 563 patients, tarlatamab plus durvalumab maintenance improved median overall survival by more than eight months and reduced the risk of death by 58% versus durvalumab alone. These are interim results.
• CRS occurred in 49.6% of patients on the combination. It was mostly grade 1–2, which is consistent with the IL-6-mediated mechanism of T-cell engagers.
• For the USMLE, link SCLC (neuroendocrine, TP53/RB1, paraneoplastic syndromes) with the mechanisms of anti-PD-L1 durvalumab and the CD3 × DLL3 bispecific tarlatamab.

This article is for educational purposes only and is not medical advice.